hOTX2
Glaucoma
About BrainEver
BrainEver is a clinical-stage biotech pioneering a novel therapeutic class based on homeoproteins—neuron maintenance and rejuvenation factors—to treat neurodegenerative diseases. The company's lead program, BREN02 (hEN1 for ALS), is in late preclinical development, supported by a recent €33M Series B financing to initiate a European clinical trial. With a pipeline spanning ALS, Parkinson's, and retinal disorders, BrainEver aims to deliver disease-modifying treatments by targeting the underlying biology of neuronal survival and function.
View full company profileAbout BrainEver
BrainEver is a clinical-stage biotech pioneering a novel therapeutic class based on homeoproteins—neuron maintenance and rejuvenation factors—to treat neurodegenerative diseases. The company's lead program, BREN02 (hEN1 for ALS), is in late preclinical development, supported by a recent €33M Series B financing to initiate a European clinical trial. With a pipeline spanning ALS, Parkinson's, and retinal disorders, BrainEver aims to deliver disease-modifying treatments by targeting the underlying biology of neuronal survival and function.
View full company profileTherapeutic Areas
Other Glaucoma Drugs
| Drug | Company | Phase |
|---|---|---|
| PREZIA Glaucoma Implant | PolyActiva | Preclinical |
| MIGS Device System | Micropoint Biotechnologies | Commercial |
| INM-088 | InMed Pharmaceuticals | Preclinical |
| OT-401 | Ocumension Therapeutics | Phase 2 |
| ANX007 | Annexon Biosciences | Phase 2 |
| PER-001 | Perfuse Therapeutics | Phase 2 |
| Glaucoma Treatment | BVI Medical | Commercial |
| MediPrint Lens (Glaucoma) | MediPrint Ophthalmics | Phase 2b |
| Glaucoma Program | Broadwing Bio | Pre-clinical |
| MSC Exosomal Eye Serum | Vitti Labs | Pre-clinical |
| BTQ1902 | Betaliq | Phase 2 |
| TODDD™ Platform | Amorphex Therapeutics | Pre-clinical |